| Original language | English |
|---|---|
| Pages (from-to) | 328-329 |
| Number of pages | 2 |
| Journal | Journal of the American College of Cardiology |
| Volume | 66 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published or Issued - 21 Jul 2015 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes. / Mani, Preethi; Uno, Kiyoko; St. John, Julie et al.
In: Journal of the American College of Cardiology, Vol. 66, No. 3, 21.07.2015, p. 328-329.Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Favorable Impact on LDL Particle Size in Response to Treatment with Pioglitazone is Associated with Less Progression of Coronary Atherosclerosis in Patients with Type 2 Diabetes
AU - Mani, Preethi
AU - Uno, Kiyoko
AU - St. John, Julie
AU - Kupfer, Stuart
AU - Perez, Alfonso
AU - Tuzcu, E. Murat
AU - Hazen, Stanley L.
AU - Nissen, Steven E.
AU - Nicholls, Stephen J.
N1 - Funding Information: Please note: Dr. Nissen has received research support to perform clinical trials through the Cleveland Clinic Coordinating Center for Clinical Research from Pfizer, AstraZeneca, Novartis, Roche, Daiichi-Sankyo, Takeda, Sanofi, Resverlogix, and Eli Lilly; and is a consultant/advisor for many pharmaceutical companies but requires them to donate all honoraria or consulting fees directly to charity so that he receives neither income nor a tax deduction. Dr. Nicholls has received speaking honoraria from AstraZeneca, Pfizer, Merck Schering-Plough, and Takeda; consulting fees from AstraZeneca, Pfizer, Merck Schering-Plough, CSL Behring, Boehringer Ingelheim, Takeda, Roche, NovoNordisk, LipoScience, Amgen, Omthera, Reseverlogix, and Anthera; and has received research support from AstraZeneca, Eli Lilly, Amgen, Takeda, Roche, Novartis, Anthera, Resverlogix, and Lipid Sciences. Drs. Perez and Kupfer are employees of Takeda Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
PY - 2015/7/21
Y1 - 2015/7/21
UR - http://www.scopus.com/inward/record.url?scp=84937426645&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2015.05.023
DO - 10.1016/j.jacc.2015.05.023
M3 - Letter
C2 - 26184626
AN - SCOPUS:84937426645
VL - 66
SP - 328
EP - 329
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
SN - 0735-1097
IS - 3
ER -